We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

142 hedge funds and large institutions have $739M invested in CytomX Therapeutics in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 62 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $1.2M

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

41% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 44

6.11% more ownership

Funds ownership: 77.05% → 83.16% (+6.1%)

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

1% more funds holding

Funds holding: 141 → 142 (+1)

12% less capital invested

Capital invested by funds: $843M → $739M (-$104M)

Holders
142
Holders Change
+1
Holders Change %
+0.71%
% of All Funds
3.25%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
26
Increased
62
Reduced
44
Closed
24
Calls
$2.74M
Puts
$1.2M
Net Calls
+$1.54M
Net Calls Change
-$1.01M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$18.3M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$16.7M
3
State Street
State Street
Massachusetts
+$14.3M
4
Renaissance Technologies
Renaissance Technologies
New York
+$11.5M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$9.63M

Top Sellers

Rank Fund Capital Flow
1
TG
TRV GP
Massachusetts
-$29M
2
Millennium Management
Millennium Management
New York
-$8.43M
3
TCM
Tekla Capital Management
Massachusetts
-$7.54M
4
PA
Perceptive Advisors
New York
-$7.33M
5
PC
PointState Capital
New York
-$4.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
151
Alambic Investment Management
California
– -$694K -24,400 Closed
JC
152
JBF Capital
Colorado
– -$692K -24,333 Closed
DZ Bank
153
DZ Bank
Germany
– -$600K -21,107 Closed
DTL
154
Dynamic Technology Lab
Singapore
– -$488K -17,178 Closed
FRM
155
Fox Run Management
Connecticut
– -$439K -15,446 Closed
Aberdeen Group
156
Aberdeen Group
United Kingdom
– -$381K -13,403 Closed
Marshall Wace
157
Marshall Wace
United Kingdom
– -$344K -12,100 Closed
VF
158
Virtu Financial
New York
– -$316K -11,123 Closed
RJA
159
Raymond James & Associates
Florida
– -$242K -8,515 Closed
MCM
160
Matarin Capital Management
New York
– -$231K -8,133 Closed
Neuberger Berman Group
161
Neuberger Berman Group
New York
– -$220K -7,735 Closed
JMPWA
162
JP Morgan Private Wealth Advisors
California
– -$216K -7,609 Closed
WG
163
Winton Group
United Kingdom
– -$205K -7,214 Closed
FAM
164
Fred Alger Management
New York
– -$114K -4,000 Closed
FDCDDQ
165
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$75.4K -2,650 Closed
Simplex Trading
166
Simplex Trading
Illinois
– -$2K -89 Closed
3 4 5 6
7

CTMX Hedge Fund Activity: Q2 2018 in Review

142 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2018, worth a combined $739M — down 12% from $843M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new CTMX positions and 24 closed out — a net gain of 2 holders — while 62 added to existing stakes and 44 trimmed.

The largest buyer was BlackRock, adding an estimated $18.3M. The largest seller was TRV GP, exiting entirely with an estimated $29M sold.

  • 142 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2018, up from 141 in Q1 2018.
  • Funds reported $739M of CytomX Therapeutics stock for Q2 2018, down 12% quarter-over-quarter.
  • 26 funds opened new CytomX Therapeutics positions in Q2 2018 and 24 closed out, a net change of +2 holders.
  • The largest CytomX Therapeutics buyer in Q2 2018 was BlackRock, an estimated $18.3M added.
  • The largest CytomX Therapeutics seller in Q2 2018 was TRV GP, an estimated $29M sold.

Based on aggregated 13F filings for Q2 2018.